VIVES is a multi-sector fund that invests in projects with a positive societal impact
Founded at the end of the nineties, NeuroTECH was co-founded by Mr. Troosters and three members of UCLouvain (Prof. C. Trullemans, Prof. Cl. Veraart and Dr. J. Delbeke).
During the first years and in...
ExeVir is a clinical-stage company developing antiviral therapies using its VHH technology platform to provide broad protection against viral infections, including coronaviruses. The platform builds...
iTeos Therapeutics targets the tumor microenvironment to boost immune cell efficiency in cancer eradication.
Immunotherapy is a revolutionary approach to cancer treatment that aims to educate the...
Chris Buyse, co-founder and Managing Partner of Fund+:
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Denis Périquet, CEO Tessares:
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Philippe Mengal, past CEO Greenwatt:
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is